Completely agree the Vision study results will show a greater...

Completely agree the Vision study results will show a greater survival benefit than the Warmth study. I'm expecting mOS to be between 12-14 months, which will be consistent with all of the other studies involving LuPSMA. This would also be a fantastic result for Veyonda.

However, I do have two concerns that may point to a slightly higher survival benefit, lets say between 14-16 months. The first is the clinical trial met both primary endpoints, which suggests survival is sufficiently greater in order to allow for multiple testing i.e. multiplicity. Of course this depends on survival (and confidence intervals) in the untreated group, but statistical significance needs to be greater to meet two primary endpoints vs a single primary endpoint. My second concern is the abstract was given a prime slot at one of the worlds greatest cancer oncology meetings.

Maybe i'm reading too much into it, but nevertheless i'm looking forward to June 7th.

GLTAH